… Before the prospective study, we performed a pilot study in seven patients with non–small-cell
lung cancer to determine the optimal scanning protocol, especially with regard to the …

… Paxillin, which is highly overexpressed in non–small-cell lung cancer (NSCLC), shows …
and can sometimes be mutated in lung cancer. Because there are various mechanisms for MET …

Until recently, non–small-cell lung cancer (NSCLC) was treated as a single disease despite
recognition of its histologic and molecular heterogeneity. Recent clinical trials, however, …

… In recent years, there has been a major paradigm shift in the management of non-small cell
lung cancer (NSCLC). NSCLC should now be further sub-classified by histology and driver …

… , detected in cells present in all tested pleural fluids obtained (from three patients with
adenocarcinoma of the lung). Conclusion: The subset of non-smallcell lung cancers that exhibits …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer (NSCLC),
developments in neoadjuvant and adjuvant treatments have been nascent by …

… DDR2 DDR2 is a RTK that binds collagen and promotes cell migration, proliferation, and
survival. DDR2 mutations were identified in squamous cell lung cancers and cell lines. In …

… may lead to the treatment of clinically indolent cancers. No … stage I non-small cell lung
cancer (NSCLC) is uncommon. … on 101,844 incident non-small cell lung cancer (NSCLC) …

Purpose: To describe the radiobiological rationale for dose-per-fraction escalation in non–small-cell
lung cancer (NSCLC) and to devise a novel Phase I scheme to implement this …

… Lung cancer is the leading cause of death from cancer among both men and women in
the United States, and non–small-cell lung cancer (… for determining lung-cancer prognosis. …